Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock Life Science Investing
Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details Life Science Investing
BetterInvesting Magazine Update on Broadridge Financial Resources Inc. and ResMed Inc. Life Science Investing
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 Life Science Investing
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 Medical Device Investing
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Life Science Investing
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference Life Science Investing
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure Life Science Investing
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy Life Science Investing
Rain Enhancement Technologies Announces Support for Colorado Weather Enhancement Paid Pilot Application, Target Install by October 2026 Life Science Investing
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference Life Science Investing
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening Medical Device Investing
